trial · primary record
Zelenectide pevedotin
Metastatic Urothelial Cancer
| Phase | Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 375 |
| Primary completion | 2028-03 |
| Primary endpoint | Cohort 1: Progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors, version 1.1(RECIST v1.1) by blinded central independent review (BICR) of optimal dose zelenectide pevedotin with pembrolizumab versus chemotherapy |
| Registry ID | NCT06225596 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:31:47.178Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06225596
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.